Abstract
Abstract
CLHSE‑1.0 is a unified, open‑hardware support architecture designed for patients receiving FDA‑approved LEQEMBI IQLIK (subcutaneous lecanemab‑irmb) for early Alzheimer’s disease. The system integrates five existing Caldwell inventions, each posted on the TDC site, and adds a caregiver micro‑dashboard, clinic integration packet, and minimal hardware starter kit to increase real‑world viability and testing potential.
CLHSE‑1.0 provides a non‑clinical safety and monitoring envelope around LEQEMBI IQLIK’s at‑home dosing model, addressing ARIA‑E/ARIA‑H symptom detection, injection‑reaction monitoring, neurologic changes, sleep‑linked deterioration, caregiver workflow, and functional decline tracking aligned with CDR‑SB domains.
CLHSE‑1.0 does not modify lecanemab, its dosing, its pharmacology, or its FDA‑approved indication.
It is intended for research‑only evaluation in dementia clinics, neurology departments, and Alzheimer’s research centers.
DISCLAIMER — CONCEPTUAL, NON‑CLINICAL, NON‑MEDICAL
This invention is a conceptual, open‑hardware research architecture intended solely for engineering exploration, usability studies, and non‑clinical evaluation.
CLHSE‑1.0 does not diagnose, treat, cure, prevent, or modify Alzheimer’s disease or any medical condition.
It does not alter LEQEMBI IQLIK (lecanemab‑irmb), its dosing, its pharmacology, or its FDA‑approved indication.
All modules described are non‑medical support systems designed for research environments only.
No clinical claims are made. No therapeutic claims are implied.
Builder‑ready. No patents. No secrets.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Caldwell, Michael Victor Mr., "CALDWELL LEQEMBI HOME‑SAFETY & SUPPORT ENGINE (CLHSE‑1.0) Unified Open‑Hardware Architecture Integrating CUDRE‑1.0, CNG‑Loop v1.0, CINHRS, BECDS v2.0, ACCS v4.0, and Caregiver/Clinic Integration Enhancements", Technical Disclosure Commons, ()
https://www.tdcommons.org/dpubs_series/10949